Evotec SE (ETR:EVT - Get Free Report) rose 1.3% during trading on Friday . The company traded as high as €7.37 ($8.57) and last traded at €7.20 ($8.37). Approximately 978,207 shares were traded during trading, a decline of 28% from the average daily volume of 1,360,000 shares. The stock had previously closed at €7.11 ($8.26).
Evotec Trading Down 2.1%
The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -7.62, a price-to-earnings-growth ratio of 0.98 and a beta of 1.05. The stock has a fifty day moving average price of €7.17 and a 200 day moving average price of €7.33.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
